Masquelet Induced-Membrane Technique

The Masquelet Induced-Membrane Technique

Definition

The Masquelet induced-membrane technique is a two-stage surgical strategy for reconstructing segmental bone defects. First described by Alain-Charles Masquelet in 1986, the technique exploits the body's foreign-body response to create a biologically privileged environment for bone grafting. In the first stage, following radical debridement of nonviable bone and soft tissue, a polymethylmethacrylate (PMMA) cement spacer is inserted into the defect and the limb is stabilised. Over six to eight weeks, a vascularised, bioactive "induced membrane" forms around the spacer. In the second stage, the spacer is carefully removed while preserving the membrane, and the resulting cavity is filled with autologous cancellous bone graft, most commonly harvested from the iliac crest or via reamer–irrigator–aspirator (RIA) from the femoral canal. The membrane acts as a biological chamber: it secretes osteoinductive and angiogenic factors—including vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-β), and bone morphogenetic protein-2 (BMP-2)—while preventing graft resorption and fibrous ingrowth.

Patient Population

Candidates for the technique are typically patients with critical-sized bone defects—generally exceeding 2 to 5 centimeters—that will not heal spontaneously. The most common causes include high-energy open fractures (particularly Gustilo-Anderson type IIIB injuries), post-traumatic osteomyelitis, infected nonunion, and defects created by tumour resection. The population skews toward young adult males, reflecting the demographics of high-energy trauma, though the technique is also applied in paediatric patients with congenital pseudarthrosis and in military casualties with blast injuries.

Anatomic Distribution

The technique is most frequently employed in the tibia, where a precarious soft-tissue envelope and high rates of open fracture make segmental defects common. The femur is the second most frequent site, followed by the humerus, forearm, and, less commonly, the hand, foot, and clavicle. Defects ranging from 4 to 25 centimeters have been successfully reconstructed, making it applicable across a remarkable range of anatomic and defect-size scenarios.

Clinical Significance

For the orthopaedic surgeon, the Masquelet technique matters for several reasons. It offers a technically accessible alternative to distraction osteogenesis (Ilizarov bone transport) and free vascularised fibular transfer, both of which demand prolonged treatment times or microsurgical expertise. The staged design accommodates infection control: antibiotic-laden cement spacers deliver high local antibiotic concentrations, making the technique especially valuable in septic nonunion. Union rates of approximately 80 to 90 percent are reported in most series, though complications—graft resorption, refracture, persistent infection, and donor-site morbidity—are not rare. Success depends critically on adherence to core principles: radical debridement, stable fixation, adequate soft-tissue coverage, atraumatic membrane preservation at the second stage, and grafting within the window of peak membrane bioactivity. Mastery of this technique has become an essential component of the modern limb reconstruction armamentarium.

View larger

The Masquelet Induced-Membrane Technique

Background and Underlying Disease Process

Segmental bone loss represents one of the most challenging problems in orthopaedic reconstruction. It arises most commonly from high-energy open fractures, debridement of infected non-union, tumour resection, and osteomyelitis. Keep two different numbers apart here, because they are often conflated. A critical-size defect — the point beyond which bone will not bridge on its own — is conventionally defined as a length over about 2 cm or loss of more than 50% of the cortical circumference; the regenerative capacity of bone is overwhelmed and the defect fills with fibrous tissue instead. That is a biological threshold, and it is convention rather than a measured cut-off. The practical threshold for choosing this operation is different and larger: most reported series reserve the induced-membrane technique for defects of roughly 2 to 5 cm and above, and the cohorts that define its results sit well beyond that — 57% of Karger's defects exceeded 5 cm, and Masquelet's original series spanned 4 to 25 cm. A 1.5 cm defect is critical-size but is usually managed by shortening, grafting or compression, not by a two-stage reconstruction.

The Masquelet technique, described by Alain-Charles Masquelet in 1986, exploits the foreign-body reaction to a polymethylmethacrylate (PMMA) cement spacer. Rather than being a nuisance, the resulting fibrous capsule — the induced membrane — is a biologically privileged structure that transforms a hostile defect into a favourable graft bed.

The Induced Membrane: Structure and Biology

The membrane matures over 4–8 weeks and possesses remarkable properties:

• Richly vascularised, with a synovial-like epithelium on its inner surface
• Secretory function, producing vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-β) and bone morphogenetic protein-2 (BMP-2). In Pelissier's rabbit study — the source of all of this — maximum BMP-2 production was at four weeks, and at that point the membrane drove human bone marrow stromal cells toward the osteoblastic lineage. Note the tension this creates with the conventional six-to-eight-week interval: the authors themselves concluded that reconstruction "could be carried out earlier than previously thought". No human trial has settled the interval.
• Mechanical containment, preventing graft resorption and soft-tissue interposition

Relevant Anatomy

Defects most frequently involve the tibia, femur and forearm. Anatomical considerations include:

The periosteal and endosteal blood supply must be respected during debridement; the nutrient artery is frequently compromised, and healing then depends on periosteal and membrane-derived vascularity.

The Two-Stage Procedure

1. First stage: radical debridement of all non-viable bone and soft tissue, skeletal stabilisation (external fixation, plate or nail), insertion of a PMMA spacer, and soft-tissue reconstruction where required.
2. Second stage (typically 6–8 weeks later): careful incision of the membrane, removal of the spacer, and filling of the cavity with morcellised autologous cancellous graft, classically harvested from the iliac crest or via reamer–irrigator–aspirator (RIA) from the femur.

Natural History and Outcomes

Left untreated, critical defects progress to atrophic non-union, deformity, chronic infection and, ultimately, limb-threatening dysfunction. With the Masquelet technique, union rates of 80–90% are reported, even in defects exceeding 10 cm, although the tibia fares less well than the femur. Failure is most often attributable to inadequate initial debridement or persistent infection rather than to graft biology. Time to union is typically 6–12 months, and patients must be counselled regarding prolonged treatment, the possibility of repeat grafting, and donor-site morbidity.

The technique's principal virtues remain its simplicity, reproducibility and independence from microsurgical expertise.

View larger

The Masquelet Induced-Membrane Technique

Overview

The Masquelet technique, first described by Alain-Charles Masquelet in 1986, is a two-stage reconstructive strategy for segmental bone defects, typically those exceeding 4–5 cm, where acute shortening or conventional grafting would fail. The surgeon should regard it as the workhorse for post-traumatic and post-infective long bone defects, particularly of the tibia and femur.

Typical History

The patient presenting for consideration of induced-membrane reconstruction usually offers one of the following narratives:

• High-energy open fracture (Gustilo IIIB/IIIC), often with segmental bone loss at the time of injury or following serial debridement
• Chronic osteomyelitis requiring segmental resection of infected, sequestrated bone
• Infected non-union, frequently after multiple failed fixation attempts
• Tumour resection, occasionally, where biological reconstruction is preferred over endoprosthesis

A careful history should document previous operations, antibiotic courses, smoking status, diabetes, and nutritional state — all of which prejudice membrane quality and graft incorporation.

Examination Findings

The interval between stages is classically 6–8 weeks, when the induced membrane — a richly vascularised, bioactive pseudo-synovial structure secreting VEGF, TGF-β1 and BMP-2 — is at its biological zenith.

Conditions and Constructs It Mimics

The induced membrane itself, and the clinical picture surrounding the technique, may be confused with several entities:

• Periosteum: the membrane behaves as a neo-periosteum, containing an osteogenic surface layer facing the cement — histologically it mimics true periosteal tissue
• Infected collection or abscess: at second-stage surgery, the fluid surrounding the spacer can resemble pus; culture and inspection are mandatory before proceeding to graft
• Foreign-body granuloma: histological appearances overlap, as the membrane is fundamentally a foreign-body reaction to polymethylmethacrylate
• Persistent non-union: slow graft incorporation on radiographs may be misread as failure; consolidation frequently requires up to a year

Key Points

• Two stages: cement spacer induces the membrane; second-stage cancellous autografting fills the defect
• Eradicate infection before Stage 2 — the technique forgives many sins, but not sepsis
• Preserve the membrane scrupulously at grafting; its violation compromises vascularity and growth factor delivery

Union rates of 80–90% are reported in contemporary series, provided soft-tissue cover is sound and infection controlled.

View larger

View larger

View larger

The Masquelet Induced-Membrane Technique: Imaging, Laboratory Assessment and Diagnostic Confirmation

Overview

The Masquelet technique remains the workhorse for reconstruction of segmental bone defects, typically following infected non-union, open fracture with bone loss, or tumour resection. Success of the second stage depends critically on rigorous assessment prior to cement spacer exchange, and the surgeon must be satisfied that infection is controlled and the membrane is biologically competent.

Imaging Appearances

Plain radiography remains the first-line investigation between stages. The surgeon should assess:

• Position and integrity of the polymethylmethacrylate (PMMA) spacer, ideally overlapping the bone ends by 1–2 cm to induce membrane over viable cortex
• Stability of fixation, with no lucency around implants
• Evidence of persistent sequestrum, periosteal reaction, or progressive osteolysis suggesting ongoing sepsis

CT offers superior delineation of defect geometry, occult sequestra and the quality of bone ends. Defect length should be measured on orthogonal reconstructions; defects exceeding 5 cm traditionally favour induced-membrane reconstruction over acute shortening, while defects beyond 10–15 cm may prompt consideration of vascularised transfer or bone transport.

MRI is valuable where residual osteomyelitis is suspected, demonstrating marrow oedema (low T1, high STIR signal), the classic penumbra sign of intraosseous abscess (a thin T1-hyperintense rim around a low-signal collection), and sinus tracts. Metal artefact reduction sequences are advisable in the presence of fixation.

Nuclear imaging — labelled leucocyte scintigraphy or FDG-PET/CT — is reserved for equivocal cases, offering high negative predictive value for excluding persistent infection.

Laboratory Workup

Serial inflammatory markers should be trending towards normal before second-stage grafting:

Vitamin D deficiency should be corrected, and smoking cessation strongly encouraged, given their deleterious effect on graft incorporation.

Diagnostic Confirmation and Biopsy Principles

Definitive exclusion of infection rests on tissue sampling, not serology. Principles mirror those established for prosthetic joint infection:

• Withhold antibiotics for at least two weeks prior to sampling where clinically safe
• Take a minimum of five deep tissue samples from representative sites (membrane, bone ends, medullary canal), each with clean, unused instruments
• Send specimens for extended-culture microbiology (including fungal and mycobacterial culture where indicated) and histopathology; more than five neutrophils per high-power field suggests active infection
• Sonication of removed spacers or implants improves organism yield in biofilm-associated infection
• Molecular techniques (16S rRNA PCR) may assist in culture-negative cases

Only when imaging, biochemistry and tissue diagnostics are concordant should the surgeon proceed to membrane preservation and autologous grafting, thereby maximising the likelihood of union.

View larger

The Masquelet Induced-Membrane Technique

Overview

The induced-membrane technique, described by Alain-Charles Masquelet, remains a cornerstone of segmental bone defect reconstruction. It is a two-stage procedure exploiting the biologically active membrane that forms around a polymethylmethacrylate (PMMA) cement spacer. The membrane is richly vascularised, secretes osteoinductive factors (BMP-2, VEGF, TGF-β), and prevents graft resorption.

When to Observe Rather Than Operate

Not every defect demands reconstruction. Conservative management or simpler measures are appropriate when:

• Defects are < 2 cm with a stable, well-vascularised envelope — acute shortening or conventional grafting often suffices
• The limb is insensate, dysvascular, or the patient's physiological reserve is poor — amputation may serve better
• Active, undrained infection persists — reconstruction before source control invites failure
• The patient cannot tolerate or comply with a prolonged, staged pathway

Indications for the Technique

• Segmental defects of 2–25 cm, typically post-traumatic, post-infective (following excision of infected non-union or osteomyelitis), or post-tumour resection
• Composite injuries where soft-tissue reconstruction can be staged alongside the first stage

Key Operative Steps

Stage One

Stage Two (typically 6–8 weeks later)

1. Incise the membrane longitudinally with care and preserve it — it is the biological chamber
2. Remove the spacer piecemeal, avoiding membrane damage
3. Freshen and open the medullary canals of both bone ends
4. Fill the chamber with morcellised autologous cancellous graft (iliac crest or RIA harvest); dilute with allograft or substitutes if volume exceeds supply (ideally ≤ 1:3 ratio)
5. Close the membrane over the graft; avoid over-compaction, which impairs revascularisation

What Changes the Plan

• Positive cultures at stage one: delay stage two, tailor antibiotics, and consider repeat debridement with spacer exchange
• Inadequate soft tissues: prioritise flap coverage before proceeding
• Membrane violation or infection at stage two: abandon grafting; return to debridement and a new spacer
• Defect > 15–20 cm or failed Masquelet: consider vascularised fibula, bone transport, or hybrid techniques
• Smoking, diabetes, poor nutrition: optimise before stage two; these are modifiable determinants of union

Summary

Success rests on uncompromising debridement, a healthy soft-tissue envelope, respect for the membrane, and patience with timing. When these principles are honoured, union rates approaching 80–90% are achievable even in hostile defects.

The Masquelet Induced-Membrane Technique: Complications, Prognosis and Surveillance

Complications

The induced-membrane technique, whilst transformative in managing segmental bone defects, carries a recognised complication profile across both stages. Reported failure rates requiring further intervention range from 10–50%, reflecting heterogeneity in defect aetiology, host physiology and technical execution.

Principal complications include:

• Infection recurrence — the most frequent cause of failure, particularly in post-traumatic and septic non-union cases. Persistent deep infection may declare itself only after second-stage grafting.
• Graft resorption and non-union — incomplete consolidation of the graft, especially in defects exceeding 6 cm or where the membrane has been damaged.
• Membrane injury during spacer removal — careless extraction compromises the membrane's vascular and osteoinductive properties.
• Stress fracture through regenerated bone, typically within the first two years.
• Donor-site morbidity — pain, haematoma or lateral cutaneous nerve injury following iliac crest or RIA (Reamer-Irrigator-Aspirator) harvest.
• Fixation failure — implant loosening or breakage during prolonged consolidation.

Prevention

Management

Recurrent infection mandates return to first principles: repeat debridement, spacer exchange and a further induced-membrane cycle. Aseptic non-union at the graft–host junction often responds to revision fixation with supplementary autograft. Stress fractures through regenerate usually heal with cast immobilisation or exchange nailing. Refractory cases may warrant conversion to bone transport, vascularised fibular grafting or, rarely in the lower limb, amputation following candid shared decision-making.

Prognosis

Union rates of 80–90% are achievable in appropriately selected patients, though 40–50% may require an additional procedure. Adverse prognostic factors include smoking, diabetes mellitus, defects greater than 8 cm, prior infection and poor soft-tissue coverage. Smoking cessation should be considered near-mandatory before the second stage.

Surveillance

Follow-up should continue for a minimum of two years:

• Clinical review at 6-weekly intervals initially, assessing pain, wound status and weight-bearing progression.
• Serial radiographs to monitor graft incorporation and corticalisation; CT where union is equivocal.
• Inflammatory markers (CRP, ESR) if infection is suspected.
• Vigilance for late stress fracture until full cortical remodelling is evident.

Patients should be counselled that consolidation is measured in months, and that patience — from surgeon and patient alike — remains integral to success.

The Masquelet Induced-Membrane Technique: Global Variation in Practice

Overview

The induced-membrane technique, described by Alain-Charles Masquelet in 1986, remains a mainstay for segmental bone defect reconstruction. Its two-stage design—cement spacer insertion with membrane induction, followed by autologous grafting at six to eight weeks—is conceptually simple, yet worldwide practice is remarkably heterogeneous. The consultant should appreciate that much of what we "know" derives from case series rather than robust comparative evidence.

Variation in Practice

Practice differs at almost every decisional node:

• Spacer composition: Plain polymethylmethacrylate (PMMA) versus antibiotic-loaded cement. Most units add gentamicin or vancomycin empirically, though Masquelet's original description used plain cement, and laboratory data suggest antibiotic loading has little effect on membrane biology.
• Interval timing: The classical 6–8 week interval is honoured more in the breach; series report second stages from 4 weeks to over 6 months, particularly where infection eradication must be confirmed.
• Graft material: Iliac crest autograft remains the reference standard, but Reamer–Irrigator–Aspirator (RIA) harvest predominates in North America and much of Europe. Extenders—allograft, tricalcium phosphate, demineralised bone matrix—are commonly added when defect volume exceeds harvestable autograft, typically in ratios up to 1:3.
• Fixation: External fixation, plating, and intramedullary nailing are all reported; nail-plus-membrane constructs are increasingly favoured for femoral and tibial defects in well-resourced settings.

Resource-Setting Considerations

In low- and middle-income countries, the technique's appeal lies precisely in avoiding microsurgical expertise and specialised frames. Series from sub-Saharan Africa and South Asia report acceptable union rates despite delayed presentation and higher infection burdens, though follow-up attrition limits interpretation.

Guideline and Registry Evidence

Here candour is required: no national or international guideline mandates a specific Masquelet protocol, and no dedicated registry exists. The evidence base comprises:

• Systematic reviews (e.g. Morelli et al., 2016) pooling heterogeneous case series, reporting union rates of roughly 80–90% but with wide confidence intervals.
• The French Society of Orthopaedic Surgery (SoFCOT) symposium data, the nearest approximation to multicentre registry evidence, describing outcomes across French centres.
• No randomised trial has directly compared induced-membrane reconstruction with distraction osteogenesis; retrospective comparisons suggest broadly equivalent union with differing complication profiles.

Summary

The Masquelet technique exemplifies a procedure diffused globally ahead of its evidence. The prudent consultant adheres to sound principles—radical debridement, stable fixation, membrane preservation at second stage—while acknowledging that spacer additives, interval timing and graft augmentation remain matters of institutional custom rather than proven doctrine.

Related pages. The alternatives for the same defect: Bone Transport Techniques and Distraction Osteogenesis with Ilizarov External Fixation and Hexapod Frame Deformity Correction, and Free Vascularised Fibula Transfer where a vascularised strut is preferred.